Breaking News Instant updates and real-time market news.

NKLA

Nikola

$13.82 /

-1.22 (-8.11%)

, GM

General Motors

$41.54 /

-0.895 (-2.11%)

06:02
12/28/20
12/28
06:02
12/28/20
06:02

JPMorgan cuts Nikola target but sees 'generally positive' news flow in 2021

JPMorgan analyst Paul Coster lowered the firm's price target on Nikola (NKLA) to $35 from $40 and keeps an Overweight rating on the shares. The reduced year-end 2021 price target reflects the execution risk associated with a "tarnished brand," Coster tells investors in a research note. The analyst, however, expects the Nikola news flow "to be less drama-filled and to turn generally positive" in 2021. The shares have traded down 50% in the last month on news that the General Motors (GM) and Republic Services (RSG) partnerships have been abandoned, Coster says. He believes Nikola was "prudent" to exit these arrangements, preserving cash for execution of the Class 8 truck initiative. GM could still play an important role as a second-source supplier of fuel cells, notes Coster. The analyst expects Nikola to post a video of a functioning Tre in January and he looks for a "steady flow" of updates for the truck in 2021.

NKLA

Nikola

$13.82 /

-1.22 (-8.11%)

GM

General Motors

$41.54 /

-0.895 (-2.11%)

RSG

Republic Services

$95.59 /

+0.445 (+0.47%)

  • 11

    Jan

NKLA Nikola
$13.82 /

-1.22 (-8.11%)

12/24/20 Loop Capital
Nikola faces 'another setback in a series of setbacks,' says Loop Capital
12/16/20
Fly Intel: Top five analyst initiations
12/16/20 Colliers
Nikola initiated with a Neutral at Colliers
12/15/20
Evercore ISI starts Nikola at In Line, says stock 'far from clean story'
GM General Motors
$41.54 /

-0.895 (-2.11%)

12/23/20 Morgan Stanley
Apple's potential EV entry represents 'new Tesla bear case,' says Morgan Stanley
12/22/20 Citi
Citi 'very skeptical' of Apple car, says Tesla most direct competitor
12/21/20 Benchmark
General Motors price target raised to $51 from $47 at Benchmark
12/17/20 Barclays
General Motors price target raised to $49 from $45 at Barclays
RSG Republic Services
$95.59 /

+0.445 (+0.47%)

11/18/20 Argus
Republic Services price target raised to $110 from $102 at Argus
10/27/20 BofA
Waste Management downgraded to Underperform on rotation risk at BofA
10/19/20 Jefferies
Republic Services upgraded to Buy from Hold at Jefferies

TODAY'S FREE FLY STORIES

Syndicate
nLight 2.206M share Spot Secondary priced at $34.00 » 07:42
03/04/21
03/04
07:42
03/04/21
07:42
LASR

nLight

$36.79 /

-0.93 (-2.47%)

The deal range was…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
LASR nLight
$36.79 /

-0.93 (-2.47%)

02/18/21 DA Davidson
nLight price target raised to $48 from $30 at DA Davidson
02/18/21 Craig-Hallum
nLight price target raised to $48 from $32 at Craig-Hallum
02/18/21 Canaccord
nLight price target raised to $53 from $27 at Canaccord
01/21/21 Berenberg
nLight assumed with a Hold at Berenberg
LASR nLight
$36.79 /

-0.93 (-2.47%)

  • 04
    Mar
LASR nLight
$36.79 /

-0.93 (-2.47%)

Downgrade
WSFS Financial downgraded to Neutral from Outperform at Boenning & Scattergood » 07:41
03/04/21
03/04
07:41
03/04/21
07:41
WSFS

WSFS Financial

$51.90 /

+0.68 (+1.33%)

Boenning &…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
WSFS WSFS Financial
$51.90 /

+0.68 (+1.33%)

WSFS WSFS Financial
$51.90 /

+0.68 (+1.33%)

03/01/21 Piper Sandler
WSFS Financial downgraded to Neutral from Overweight at Piper Sandler
02/25/21 Keefe Bruyette
WSFS Financial downgraded to Market Perform from Outperform at Keefe Bruyette
04/01/20 Keefe Bruyette
WSFS Financial upgraded to Outperform from Market Perform at Keefe Bruyette
WSFS WSFS Financial
$51.90 /

+0.68 (+1.33%)

WSFS WSFS Financial
$51.90 /

+0.68 (+1.33%)

Hot Stocks
Skylight Health to acquire three U.S. primary care practices » 07:41
03/04/21
03/04
07:41
03/04/21
07:41
SHGFF

Skylight Health

$0.00 /

+ (+0.00%)

Skylight Health Group is…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SHGFF Skylight Health
$0.00 /

+ (+0.00%)

SHGFF Skylight Health
$0.00 /

+ (+0.00%)

02/24/21 Raymond James
Skylight Health initiated with an Outperform at Raymond James
Hot Stocks
Dyne Therapeutics expects cash to fund requirements into 2H24 » 07:40
03/04/21
03/04
07:40
03/04/21
07:40
DYN

Dyne Therapeutics

$16.73 /

-1.02 (-5.75%)

In January 2021, Dyne…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DYN Dyne Therapeutics
$16.73 /

-1.02 (-5.75%)

DYN Dyne Therapeutics
$16.73 /

-1.02 (-5.75%)

02/09/21
Dyne Therapeutics initiated with a Buy at JonesTrading
01/07/21 Piper Sandler
Dyne Therapeutics potential beneficiary of Sarepta's SRP-9001 miss, says Piper
10/12/20 Jefferies
Dyne Therapeutics initiated with a Buy at Jefferies
10/12/20 JPMorgan
Dyne Therapeutics initiated with an Overweight at JPMorgan
DYN Dyne Therapeutics
$16.73 /

-1.02 (-5.75%)

  • 21
    Jan
  • 17
    Sep
DYN Dyne Therapeutics
$16.73 /

-1.02 (-5.75%)

Earnings
Dyne Therapeutics reports Q4 EPS (64c), consensus (37c) » 07:39
03/04/21
03/04
07:39
03/04/21
07:39
DYN

Dyne Therapeutics

$16.73 /

-1.02 (-5.75%)

"2020 was a…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
DYN Dyne Therapeutics
$16.73 /

-1.02 (-5.75%)

DYN Dyne Therapeutics
$16.73 /

-1.02 (-5.75%)

02/09/21
Dyne Therapeutics initiated with a Buy at JonesTrading
01/07/21 Piper Sandler
Dyne Therapeutics potential beneficiary of Sarepta's SRP-9001 miss, says Piper
10/12/20 Jefferies
Dyne Therapeutics initiated with a Buy at Jefferies
10/12/20 JPMorgan
Dyne Therapeutics initiated with an Overweight at JPMorgan
DYN Dyne Therapeutics
$16.73 /

-1.02 (-5.75%)

  • 21
    Jan
  • 17
    Sep
DYN Dyne Therapeutics
$16.73 /

-1.02 (-5.75%)

Hot Stocks
Arbutus Biopharma sees cash runway into 3Q22 » 07:38
03/04/21
03/04
07:38
03/04/21
07:38
ABUS

Arbutus Biopharma

$3.64 /

-0.19 (-4.97%)

Arbutus had cash, cash…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ABUS Arbutus Biopharma
$3.64 /

-0.19 (-4.97%)

ABUS Arbutus Biopharma
$3.64 /

-0.19 (-4.97%)

12/17/20 H.C. Wainwright
Arbutus Biopharma initiated with a Buy at H.C. Wainwright
09/15/20 Chardan
Arbutus HBV data 'could represent a turning point,' says Chardan
07/27/20 B. Riley FBR
Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
ABUS Arbutus Biopharma
$3.64 /

-0.19 (-4.97%)

ABUS Arbutus Biopharma
$3.64 /

-0.19 (-4.97%)

Initiation
Histogen initiated with a Buy at Canaccord » 07:38
03/04/21
03/04
07:38
03/04/21
07:38
HSTO

Histogen

$1.15 /

-0.035 (-2.95%)

Canaccord Genuity analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
HSTO Histogen
$1.15 /

-0.035 (-2.95%)

  • 31
    Dec
HSTO Histogen
$1.15 /

-0.035 (-2.95%)

Earnings
Arbutus Biopharma reports 2020 EPS ($1.00), consensus (98c) » 07:38
03/04/21
03/04
07:38
03/04/21
07:38
ABUS

Arbutus Biopharma

$3.64 /

-0.19 (-4.97%)

Reports 2020 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ABUS Arbutus Biopharma
$3.64 /

-0.19 (-4.97%)

ABUS Arbutus Biopharma
$3.64 /

-0.19 (-4.97%)

12/17/20 H.C. Wainwright
Arbutus Biopharma initiated with a Buy at H.C. Wainwright
09/15/20 Chardan
Arbutus HBV data 'could represent a turning point,' says Chardan
07/27/20 B. Riley FBR
Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
ABUS Arbutus Biopharma
$3.64 /

-0.19 (-4.97%)

ABUS Arbutus Biopharma
$3.64 /

-0.19 (-4.97%)

Hot Stocks
Dicerna, Roche begin combo trial of GalXC for chronic HBV treatment » 07:37
03/04/21
03/04
07:37
03/04/21
07:37
DRNA

Dicerna

$29.00 /

-0.52 (-1.76%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

Dicerna Pharmaceuticals…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
DRNA Dicerna
$29.00 /

-0.52 (-1.76%)

RHHBY Roche
$0.00 /

+ (+0.00%)

DRNA Dicerna
$29.00 /

-0.52 (-1.76%)

03/02/21 H.C. Wainwright
Dicerna price target raised to $40 from $35 at H.C. Wainwright
03/02/21 Chardan
Dicerna price target raised to $34 from $25 at Chardan
03/01/21 B. Riley Securities
Dicerna price target raised to $40 from $37 at B. Riley Securities
01/11/21 B. Riley Securities
Dicerna price target raised to $37 from $30 at B. Riley Securities
RHHBY Roche
$0.00 /

+ (+0.00%)

03/03/21 Goldman Sachs
Adaptive Biotechnologies downgraded to Neutral from Buy at Goldman Sachs
02/25/21 Berenberg
Roche price target lowered to CHF 320 from CHF 325 at Berenberg
02/24/21 Morgan Stanley
Roche price target lowered to CHF 345 from CHF 365 at Morgan Stanley
02/23/21 BofA
BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list
DRNA Dicerna
$29.00 /

-0.52 (-1.76%)

RHHBY Roche
$0.00 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

DRNA Dicerna
$29.00 /

-0.52 (-1.76%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Upgrade
Agricultural Bank of China upgraded to Buy from Neutral at Goldman Sachs » 07:37
03/04/21
03/04
07:37
03/04/21
07:37
ACGBY

Agricultural Bank of China

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ACGBY Agricultural Bank of China
$0.00 /

+ (+0.00%)

04/03/20 Jefferies
Agricultural Bank of China initiated with a Buy at Jefferies
Hot Stocks
Verrica Pharmaceuticals expects cash to support operations at least into 1Q22 » 07:36
03/04/21
03/04
07:36
03/04/21
07:36
VRCA

Verrica Pharmaceuticals

$15.18 /

+0.97 (+6.83%)

As of December 31, 2020,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$15.18 /

+0.97 (+6.83%)

VRCA Verrica Pharmaceuticals
$15.18 /

+0.97 (+6.83%)

12/24/20 Cowen
Verrica approval for molluscum likely in Q3 of 2021, says Cowen
12/24/20 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $21 from $18 at H.C. Wainwright
07/15/20 BofA
Verrica Pharmaceuticals downgraded to Neutral from Buy at BofA
06/30/20 H.C. Wainwright
Verrica Pharmaceuticals price target lowered to $18 from $24 at H.C. Wainwright
VRCA Verrica Pharmaceuticals
$15.18 /

+0.97 (+6.83%)

Upgrade
Canaccord upgrades Okta to Buy on recent selloff, accretive acquisition » 07:36
03/04/21
03/04
07:36
03/04/21
07:36
OKTA

Okta

$242.42 /

-16.595 (-6.41%)

Canaccord analyst T.…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
OKTA Okta
$242.42 /

-16.595 (-6.41%)

OKTA Okta
$242.42 /

-16.595 (-6.41%)

06:53 Today Deutsche Bank
Okta price target lowered to $270 from $313 at Deutsche Bank
06:45 Today Mizuho
Okta price target lowered to $255 from $305 at Mizuho
06:37 Today Baird
Okta price target lowered to $240 from $275 at Baird
06:06 Today Piper Sandler
Okta price target lowered to $235 from $250 at Piper Sandler
OKTA Okta
$242.42 /

-16.595 (-6.41%)

OKTA Okta
$242.42 /

-16.595 (-6.41%)

OKTA Okta
$242.42 /

-16.595 (-6.41%)

Hot Stocks
Verrica says Torii exercises option to acquire license for VP-102 » 07:35
03/04/21
03/04
07:35
03/04/21
07:35
VRCA

Verrica Pharmaceuticals

$15.18 /

+0.97 (+6.83%)

On March 2, Torii…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$15.18 /

+0.97 (+6.83%)

VRCA Verrica Pharmaceuticals
$15.18 /

+0.97 (+6.83%)

12/24/20 Cowen
Verrica approval for molluscum likely in Q3 of 2021, says Cowen
12/24/20 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $21 from $18 at H.C. Wainwright
07/15/20 BofA
Verrica Pharmaceuticals downgraded to Neutral from Buy at BofA
06/30/20 H.C. Wainwright
Verrica Pharmaceuticals price target lowered to $18 from $24 at H.C. Wainwright
VRCA Verrica Pharmaceuticals
$15.18 /

+0.97 (+6.83%)

Upgrade
Postal Savings Bank of China upgraded to Conviction Buy at Goldman Sachs » 07:34
03/04/21
03/04
07:34
03/04/21
07:34
PSTVY

Postal Savings Bank of China

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Hot Stocks
Verrica Pharmaceuticals resubmits NDA for VP-102 » 07:34
03/04/21
03/04
07:34
03/04/21
07:34
VRCA

Verrica Pharmaceuticals

$15.18 /

+0.97 (+6.83%)

The Company recently…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$15.18 /

+0.97 (+6.83%)

VRCA Verrica Pharmaceuticals
$15.18 /

+0.97 (+6.83%)

12/24/20 Cowen
Verrica approval for molluscum likely in Q3 of 2021, says Cowen
12/24/20 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $21 from $18 at H.C. Wainwright
07/15/20 BofA
Verrica Pharmaceuticals downgraded to Neutral from Buy at BofA
06/30/20 H.C. Wainwright
Verrica Pharmaceuticals price target lowered to $18 from $24 at H.C. Wainwright
VRCA Verrica Pharmaceuticals
$15.18 /

+0.97 (+6.83%)

Earnings
Syros Pharmaceuticals reports Q4 EPS (62c), consensus (50c) » 07:33
03/04/21
03/04
07:33
03/04/21
07:33
SYRS

Syros Pharmaceuticals

$8.33 /

-0.87 (-9.46%)

Reports Q4 revenue $5.7M,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SYRS Syros Pharmaceuticals
$8.33 /

-0.87 (-9.46%)

SYRS Syros Pharmaceuticals
$8.33 /

-0.87 (-9.46%)

11/10/20 Brookline
Syros Pharmaceuticals initiated with a Buy at Brookline
11/05/20 Roth Capital
Syros' SY-1425+Aza could be competitive in multiple settings, says Roth Capital
11/04/20
Fly Intel: Top five analyst upgrades
11/04/20 H.C. Wainwright
Syros Pharmaceuticals upgraded to Buy from Neutral at H.C. Wainwright
SYRS Syros Pharmaceuticals
$8.33 /

-0.87 (-9.46%)

  • 20
    Jan
SYRS Syros Pharmaceuticals
$8.33 /

-0.87 (-9.46%)

General news
Challenger Job-Cut Report Level data reported » 07:33
03/04/21
03/04
07:33
03/04/21
07:33

February Challenger…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Earnings
Verrica Pharmaceuticals reporrts Q4 EPS (52c), consensus (42c) » 07:33
03/04/21
03/04
07:33
03/04/21
07:33
VRCA

Verrica Pharmaceuticals

$15.18 /

+0.97 (+6.83%)

"Over the past year,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$15.18 /

+0.97 (+6.83%)

VRCA Verrica Pharmaceuticals
$15.18 /

+0.97 (+6.83%)

12/24/20 Cowen
Verrica approval for molluscum likely in Q3 of 2021, says Cowen
12/24/20 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $21 from $18 at H.C. Wainwright
07/15/20 BofA
Verrica Pharmaceuticals downgraded to Neutral from Buy at BofA
06/30/20 H.C. Wainwright
Verrica Pharmaceuticals price target lowered to $18 from $24 at H.C. Wainwright
VRCA Verrica Pharmaceuticals
$15.18 /

+0.97 (+6.83%)

Downgrade
Yext downgraded to Market Perform on growth headwinds at William Blair » 07:32
03/04/21
03/04
07:32
03/04/21
07:32
YEXT

Yext

$16.55 /

-1.16 (-6.55%)

William Blair analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
YEXT Yext
$16.55 /

-1.16 (-6.55%)

YEXT Yext
$16.55 /

-1.16 (-6.55%)

05:36 Today William Blair
Yext downgraded to Market Perform from Outperform at William Blair
12/04/20 DA Davidson
Yext price target lowered to $20.50 from $22 at DA Davidson
12/04/20 Truist
Yext growth should pick up next year, says Truist
07/09/20 Needham
Yext price target raised to $21 from $19 at Needham
YEXT Yext
$16.55 /

-1.16 (-6.55%)

YEXT Yext
$16.55 /

-1.16 (-6.55%)

Hot Stocks
DraftKings becomes 'Official Sportsbook, Daily Fantasy Partner' of UFC » 07:32
03/04/21
03/04
07:32
03/04/21
07:32
DKNG

DraftKings

$65.75 /

-2.785 (-4.06%)

DraftKings will become…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DKNG DraftKings
$65.75 /

-2.785 (-4.06%)

DKNG DraftKings
$65.75 /

-2.785 (-4.06%)

03/01/21 Craig-Hallum
DraftKings price target raised to $70 from $65 at Craig-Hallum
03/01/21 Canaccord
DraftKings price target raised to $80 from $65 at Canaccord
03/01/21 Northland
DraftKings price target raised to $70 from $55 at Northland
03/01/21 Benchmark
DraftKings price target raised to $69 from $66 at Benchmark
DKNG DraftKings
$65.75 /

-2.785 (-4.06%)

  • 07
    Oct
  • 19
    Jun
DKNG DraftKings
$65.75 /

-2.785 (-4.06%)

DKNG DraftKings
$65.75 /

-2.785 (-4.06%)

DKNG DraftKings
$65.75 /

-2.785 (-4.06%)

Hot Stocks
CureVac and Novartis in initial pact on Covid vaccine candidate » 07:31
03/04/21
03/04
07:31
03/04/21
07:31
CVAC

CureVac

$83.44 /

-9.76 (-10.47%)

, NVS

Novartis

$84.16 /

-0.635 (-0.75%)

CureVac (CVAC) and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CVAC CureVac
$83.44 /

-9.76 (-10.47%)

NVS Novartis
$84.16 /

-0.635 (-0.75%)

CVAC CureVac
$83.44 /

-9.76 (-10.47%)

01/07/21 Morgan Stanley
CureVac COVID-19 deal provides 'sentiment boost' for Bayer, says Morgan Stanley
12/10/20 Credit Suisse
CureVac downgraded to Underperform on rising valuation at Credit Suisse
12/10/20 Credit Suisse
CureVac downgraded to Underperform from Neutral at Credit Suisse
11/02/20 Piper Sandler
CureVac's positive vaccine data bodes well for Arcturus's ARCT-021, says Piper
NVS Novartis
$84.16 /

-0.635 (-0.75%)

03/01/21 Oppenheimer
Homology Medicines loses potential source of upside, says Oppenheimer
02/02/21 Morgan Stanley
Novartis price target lowered to CHF 102 from CHF 104 at Morgan Stanley
02/01/21 Truist
iRhythm price target lowered to $220 from $265 at Truist
02/01/21 Cowen
Novartis downgraded to Market Perform after 'tepid' guidance at Cowen
NVS Novartis
$84.16 /

-0.635 (-0.75%)

  • 28
    Jan
  • 14
    Aug
CVAC CureVac
$83.44 /

-9.76 (-10.47%)

NVS Novartis
$84.16 /

-0.635 (-0.75%)

CVAC CureVac
$83.44 /

-9.76 (-10.47%)

NVS Novartis
$84.16 /

-0.635 (-0.75%)

CVAC CureVac
$83.44 /

-9.76 (-10.47%)

Hot Stocks
Dyne Therapeutics appoints Wildon Farwell as CMO » 07:30
03/04/21
03/04
07:30
03/04/21
07:30
DYN

Dyne Therapeutics

$16.73 /

-1.02 (-5.75%)

, BIIB

Biogen

$266.84 /

-3.2 (-1.19%)

Dyne Therapeutics (DYN)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DYN Dyne Therapeutics
$16.73 /

-1.02 (-5.75%)

BIIB Biogen
$266.84 /

-3.2 (-1.19%)

DYN Dyne Therapeutics
$16.73 /

-1.02 (-5.75%)

02/09/21
Dyne Therapeutics initiated with a Buy at JonesTrading
01/07/21 Piper Sandler
Dyne Therapeutics potential beneficiary of Sarepta's SRP-9001 miss, says Piper
10/12/20 Jefferies
Dyne Therapeutics initiated with a Buy at Jefferies
10/12/20 JPMorgan
Dyne Therapeutics initiated with an Overweight at JPMorgan
BIIB Biogen
$266.84 /

-3.2 (-1.19%)

02/17/21 Cantor Fitzgerald
Biogen price target lowered to $268 from $278 at Cantor Fitzgerald
02/08/21 Citi
Expert sees Biogen aducanumab approval 50/50 at best, says Citi
02/04/21 SVB Leerink
Biogen price target lowered to $380 from $430 at SVB Leerink
02/04/21 Credit Suisse
Biogen price target lowered to $338 from $350 at Credit Suisse
DYN Dyne Therapeutics
$16.73 /

-1.02 (-5.75%)

BIIB Biogen
$266.84 /

-3.2 (-1.19%)

  • 21
    Jan
  • 17
    Sep
BIIB Biogen
$266.84 /

-3.2 (-1.19%)

DYN Dyne Therapeutics
$16.73 /

-1.02 (-5.75%)

BIIB Biogen
$266.84 /

-3.2 (-1.19%)

BIIB Biogen
$266.84 /

-3.2 (-1.19%)

BIIB Biogen
$266.84 /

-3.2 (-1.19%)

Downgrade
Regency Centers downgraded to Hold from Buy at Argus » 07:29
03/04/21
03/04
07:29
03/04/21
07:29
REG

Regency Centers

$56.67 /

+2.525 (+4.66%)

Argus analyst Angus…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
REG Regency Centers
$56.67 /

+2.525 (+4.66%)

REG Regency Centers
$56.67 /

+2.525 (+4.66%)

07:27 Today Argus
Regency Centers downgraded to Hold from Buy at Argus
01/25/21 Compass Point
Regency Centers upgraded to Buy from Neutral at Compass Point
12/30/20 Truist
Regency Centers price target raised to $50 from $45 at Truist
08/19/20
Fly Intel: Top five analyst downgrades
REG Regency Centers
$56.67 /

+2.525 (+4.66%)

REG Regency Centers
$56.67 /

+2.525 (+4.66%)

Initiation
Open Lending initiated with an Outperform at William Blair » 07:29
03/04/21
03/04
07:29
03/04/21
07:29
LPRO

Open Lending

$38.72 /

-1.3 (-3.25%)

William Blair analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LPRO Open Lending
$38.72 /

-1.3 (-3.25%)

LPRO Open Lending
$38.72 /

-1.3 (-3.25%)

02/10/21 Needham
Open Lending initiated with a Buy at Needham
01/20/21 DA Davidson
Open Lending price target raised to $45 from $31 at DA Davidson
01/04/21 Deutsche Bank
Open Lending named 'Catalyst Call: Buy Idea' at Deutsche Bank
01/04/21 Stephens
Brinker, LiveRamp and Vonage among 2021 best ideas at Stephens
  • 10
    Dec
LPRO Open Lending
$38.72 /

-1.3 (-3.25%)

Hot Stocks
Hookipa Pharma announces publication on alternating 2-vector cancer therapeutics » 07:29
03/04/21
03/04
07:29
03/04/21
07:29
HOOK

Hookipa Pharma

$12.00 /

+0.05 (+0.42%)

HOOKIPA Pharma announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
HOOK Hookipa Pharma
$12.00 /

+0.05 (+0.42%)

HOOK Hookipa Pharma
$12.00 /

+0.05 (+0.42%)

11/30/20 JMP Securities
Hookipa Pharma price target raised to $25 from $19 at JMP Securities
11/03/20
Fly Intel: Top five analyst initiations
11/03/20 Truist
Hookipa Pharma initiated with a Buy at Truist
11/03/20 Truist
Hookipa Pharma initiated with a Buy at Truist
HOOK Hookipa Pharma
$12.00 /

+0.05 (+0.42%)

  • 09
    Dec
HOOK Hookipa Pharma
$12.00 /

+0.05 (+0.42%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.